Daniel J Drucker

Toronto, Canada

Daniel J Drucker

This inventor holds 33 USPTO granted patents and 3 published patent applications, plus 6 CIPO patents and 5 EPO patents, primarily in Gastrointestinal Therapeutics. Top assignees: 1149336 Ontario, Inc., Tufts University, New England Medical Center Hospitals. Inc.. Active years: 1998-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel J Drucker. Retrieved from https://idiyas.com/inventor/daniel-j-drucker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 

% Patents Active = 51.5

 

 

Average Co-Inventor Count = 1.5

ph-index = 17

Forward Citations = 882(Granted Patents)


Location History:

  • Ontario, CA (2000 - 2003)
  • Ontariio, CA (2004)
  • Toronto, CA (1998 - 2015)

Company Filing History:


Years Active: 1998-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
GLP-1 Agonist
Glucose Metabolism
Gastrointestinal Tract
GLP-2 Analogs
Intestinal Function
Appetite Suppression
Proexendin
Intestinotrophic Peptides
Therapeutic Use
Polynucleotides
Central Nervous System
33 patents (USPTO):Explore Patents

Title: Pioneering Medical Inventor: Daniel J. Drucker Introduction: Daniel J. Drucker, a renowned inventor based in Toronto, Canada, has left an indelible mark on the field of medical research with his innovative contributions. With a total of 33 patents to his name, Dr. Drucker's work focuses on improving healthcare and advancing biotechnology. Latest Patents: 1. Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist: Dr. Drucker's invention provides a groundbreaking method for treating conditions affecting the small or large intestine by administering a GLP-1 receptor agonist. This method aims to enhance intestinal functioning, prevent damage, and alleviate inflammation in patients. 2. Methods of regulating glucose metabolism, and reagents related thereto: Another significant patent by Dr. Drucker revolves around modifying and regulating glucose metabolism. By administering an inhibitor of dipeptidylpeptidase IV (DPIV), this method aims to increase the plasma half-life of GLP-1 without compromising the animal's immune system. Career Highlights: Throughout his illustrious career, Dr. Drucker has made substantial contributions to the medical field. His focus on gastrointestinal health and glucose metabolism has led to innovative solutions that have the potential to revolutionize treatment methods for various conditions. Collaborations: Dr. Drucker has collaborated with esteemed professionals in his field, including Andrew G. Plaut and William W. Bachovchin. These partnerships have further enriched his research and have resulted in groundbreaking inventions that have the potential to positively impact healthcare worldwide. Conclusion: Daniel Drucker is an endocrinologist from Toronto who discovered a hormone called GLP-1 in 1984. This hormone helps control blood sugar and appetite. Many years later, a drug called semaglutide, which mimics GLP-1, proved effective for weight loss. This led to the creation of Ozempic and similar drugs like Wegovy, Mounjaro, and Rybelsus. These medications are now widely used to help people with diabetes and obesity. Dr. Drucker continues his research, aiming to develop even better treatments.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…